"
Team:USTC CHINA/Project/AdvancingWork
From 2013.igem.org
| Line 63: | Line 63: | ||
<div class="basic-bar"> | <div class="basic-bar"> | ||
<h1>Introduction<h1> | <h1>Introduction<h1> | ||
| - | <p>According to our experiment result, we have proved the secretion and expression possibility of TD1-antigen, TD1-adjuvant, and the antigenicity of TD1-antigen after transdermal process. So in the following experiments, we decided to utilize B.subtilis WB800N as engineered bacteria, plus shuttle vector pHT43 as secretion vector to build the B.subtilis secretory expression system. On top of this, we have taken advantage of different kinds of TD1-antigen, testing HBsAg, PA, Ag85b that have been applied into the market to check the universal property of TD1-antigen. Besides, reporters essential during real application have been found to realize the final circuit.<p> | + | <p align="justify">According to our experiment result, we have proved the secretion and expression possibility of TD1-antigen, TD1-adjuvant, and the antigenicity of TD1-antigen after transdermal process. So in the following experiments, we decided to utilize B.subtilis WB800N as engineered bacteria, plus shuttle vector pHT43 as secretion vector to build the B.subtilis secretory expression system. On top of this, we have taken advantage of different kinds of TD1-antigen, testing HBsAg, PA, Ag85b that have been applied into the market to check the universal property of TD1-antigen. Besides, reporters essential during real application have been found to realize the final circuit.<p> |
| Line 74: | Line 74: | ||
<div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig4. fluorescent microscope shows the expression of GFP in WB800N</div> | <div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig4. fluorescent microscope shows the expression of GFP in WB800N</div> | ||
<div><h3>2.Expression of TD1-antigen/adjuvant</h3></div> | <div><h3>2.Expression of TD1-antigen/adjuvant</h3></div> | ||
| - | <div><p>In order to realize the secretory expression in B.subtilis, we inserted signal peptide between promoter and the TD1-Antigen/adjuvant sequence to secrete our recombinant protein. GFP was chosen to check the reliability of this circuit. After large amounts of experiments, GFP has finally been found via fluorescence microscope.</p></div> | + | <div><p align="justify">In order to realize the secretory expression in B.subtilis, we inserted signal peptide between promoter and the TD1-Antigen/adjuvant sequence to secrete our recombinant protein. GFP was chosen to check the reliability of this circuit. After large amounts of experiments, GFP has finally been found via fluorescence microscope.</p></div> |
<img src="https://static.igem.org/mediawiki/2013/f/f0/Pctc-sp-td1-antigenadjuvent.png"width="580" height="120" /> | <img src="https://static.igem.org/mediawiki/2013/f/f0/Pctc-sp-td1-antigenadjuvent.png"width="580" height="120" /> | ||
| - | <div><p>Then, three kinds of recombinant antigen, TD1-HBsAg, TD1-PA, TD1-Ag85b, and recombinant immunologic adjuvant were designed. The earliest successful protein TD1-LTB can not only be observed clear stripes in SDS-PAGE, but also be proved according to HPLC-MS.</p></div> | + | <div><p align="justify">Then, three kinds of recombinant antigen, TD1-HBsAg, TD1-PA, TD1-Ag85b, and recombinant immunologic adjuvant were designed. The earliest successful protein TD1-LTB can not only be observed clear stripes in SDS-PAGE, but also be proved according to HPLC-MS.</p></div> |
<img src="https://static.igem.org/mediawiki/igem.org/f/fd/20-%E6%9E%AF%E8%8D%89%E8%9B%8B%E7%99%BD%E8%A1%A8%E8%BE%BE.jpg" width="580" height="300"> | <img src="https://static.igem.org/mediawiki/igem.org/f/fd/20-%E6%9E%AF%E8%8D%89%E8%9B%8B%E7%99%BD%E8%A1%A8%E8%BE%BE.jpg" width="580" height="300"> | ||
<div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig5. SDS PAGE shows the expression of LTB in WB800N</div> | <div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig5. SDS PAGE shows the expression of LTB in WB800N</div> | ||
| Line 84: | Line 84: | ||
<div><h2>TWO: Neomycin resistance of WB800N</h2></div> | <div><h2>TWO: Neomycin resistance of WB800N</h2></div> | ||
<div><h3>Selection on the of resistance of B.subtilis WB800N against neomycin</h3> | <div><h3>Selection on the of resistance of B.subtilis WB800N against neomycin</h3> | ||
| - | <p>As WB800N is a novel secretory expression system, most of whose parameters remain unclear, among which the chief problem is that its unique resistance against neomycin has never been quantitatively analyzed, and our work made up for this blank.</p></div> | + | <p align="justify">As WB800N is a novel secretory expression system, most of whose parameters remain unclear, among which the chief problem is that its unique resistance against neomycin has never been quantitatively analyzed, and our work made up for this blank.</p></div> |
<img src="https://static.igem.org/mediawiki/2013/f/f7/Xinmeisu.png" width="580" height="300"> | <img src="https://static.igem.org/mediawiki/2013/f/f7/Xinmeisu.png" width="580" height="300"> | ||
<div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig6. Selection on the of resistance of B.subtilis WB800N against neomycin</div> | <div class="atfigure" align="center" style="width:580px;font-size:14px;">Fig6. Selection on the of resistance of B.subtilis WB800N against neomycin</div> | ||
| - | <div><p>We have figured it out that the best concentration of neomycin for selection use is 128mg/ml.</p></div> | + | <div><p align="justify">We have figured it out that the best concentration of neomycin for selection use is 128mg/ml.</p></div> |
<br></br> | <br></br> | ||
<br></br> | <br></br> | ||
| Line 100: | Line 100: | ||
<br></br> | <br></br> | ||
<h3 align="left">Mice Experiment</h3> | <h3 align="left">Mice Experiment</h3> | ||
| - | <br></br><p align=" | + | <br></br><p align="justify">This year our team achieved a remarkable breakthrough in the history of iGEM by not only fulfilling molecular biology experiments but also trying animal experiments. To verify that our T-Vaccine possesses immunogenicity and is able to trigger valid immune memory in mice like traditional vaccines, we started advancing work in SPF laboratory of our university. As mice experiments are costly and time-consuming, our further results will be announced soon. We also hope T-Vaccine will be available for every family to realize our final dream: A World without Needles!</p><br></br> |
<img src="https://static.igem.org/mediawiki/2013/0/02/DSC_0088.jpg"></br></br> | <img src="https://static.igem.org/mediawiki/2013/0/02/DSC_0088.jpg"></br></br> | ||
<div class="atfigure" align="center" style="width:580px; font-size:14px">Fig9. We were observing mice</div> | <div class="atfigure" align="center" style="width:580px; font-size:14px">Fig9. We were observing mice</div> | ||
Revision as of 10:44, 28 October 2013
Introduction
According to our experiment result, we have proved the secretion and expression possibility of TD1-antigen, TD1-adjuvant, and the antigenicity of TD1-antigen after transdermal process. So in the following experiments, we decided to utilize B.subtilis WB800N as engineered bacteria, plus shuttle vector pHT43 as secretion vector to build the B.subtilis secretory expression system. On top of this, we have taken advantage of different kinds of TD1-antigen, testing HBsAg, PA, Ag85b that have been applied into the market to check the universal property of TD1-antigen. Besides, reporters essential during real application have been found to realize the final circuit.
ONE: Expression of TD1-"X" in WB800N
1.Expression of TD1-GFP
2.Expression of TD1-antigen/adjuvant
In order to realize the secretory expression in B.subtilis, we inserted signal peptide between promoter and the TD1-Antigen/adjuvant sequence to secrete our recombinant protein. GFP was chosen to check the reliability of this circuit. After large amounts of experiments, GFP has finally been found via fluorescence microscope.
Then, three kinds of recombinant antigen, TD1-HBsAg, TD1-PA, TD1-Ag85b, and recombinant immunologic adjuvant were designed. The earliest successful protein TD1-LTB can not only be observed clear stripes in SDS-PAGE, but also be proved according to HPLC-MS.
TWO: Neomycin resistance of WB800N
Selection on the of resistance of B.subtilis WB800N against neomycin
As WB800N is a novel secretory expression system, most of whose parameters remain unclear, among which the chief problem is that its unique resistance against neomycin has never been quantitatively analyzed, and our work made up for this blank.
We have figured it out that the best concentration of neomycin for selection use is 128mg/ml.
THREE: Mice Experiment is in Progress
Specific Pathogen Free (SPF) Laboratory
Specific Pathogen Free is a term used for laboratory animals that are guaranteed free of particular pathogens. Use of SPF animals ensures that specified diseases do not interfere with an experiment. For example, absence of respiratory pathogens such as influenza is desirable when investigating a drug's effect on lung function.
Mice Experiment
This year our team achieved a remarkable breakthrough in the history of iGEM by not only fulfilling molecular biology experiments but also trying animal experiments. To verify that our T-Vaccine possesses immunogenicity and is able to trigger valid immune memory in mice like traditional vaccines, we started advancing work in SPF laboratory of our university. As mice experiments are costly and time-consuming, our further results will be announced soon. We also hope T-Vaccine will be available for every family to realize our final dream: A World without Needles!
